Amgen Chairman and CEO Robert Bradway, provides insight to product innovation, the impact from the political cycle and the outlook for M&A. » Read More
Pete Najarian reveals 3 biotechs he feels provide the most bang for the buck?
Stocks declined Monday, led by financials after two more banks folded. Oil ticked higher after three straight weeks of decline.
Stocks were mixed Monday as banks rallied and oil gained more than $1 a barrel.
Shares of Amgen surged after the company reported positive trial results for its osteoporosis drug candidate denosumab—which one analyst terms "a future blockbuster."
Amgen surprised the market late on a summer Friday by announcing positive test results from the big, crucial study of its experimental osteoporosis drug. The stock shot up after hours and continues to rally this morning.
In the last month healthcare has emerged as the best performing sector in the S&P. Are drug makers a cure for your portfolio in this economic downturn?
An analyst predicts that gold will head into a bull market, and Washington Mutual increases its liquidity position. The following are today's top videos:
Amgen shares leaped in late trading Friday after the company said a pivotal trial of its experimental osteoporosis drug denosumab met its goal of significantly reducing the risk of bone fracture in post-menopausal women.
To give investors an edge, CNBC asked the market experts for their best trades now.
Fearing the two largest U.S. mortgage finance companies need a government bailout, investors pushed stocks lower Friday. What's the "Word On The Street?"
Big pharma makes strange bedfellows. Pfizer, Merck and Eli Lilly this morning announced they've launched a joint venture of sorts called, "Enlight Biosciences". They're doing it with the help of the Boston-based VC firm PureTech Ventures.
The S&P closed 20% below its all-time high set in October, making it the last of the three major U.S. stock indexes to fall into a bear market. What's the "Word on the Street?"
During the short holiday week, volatility ruled the markets, impacted by record oil prices, economic data, the auto industry and financials. How did the markets stack up?
Ahead of the long holiday weekend I thought this would be as good a time as any to once again go through the "Pharma's Market" mailbag. A couple of blog readers complained about my "short" story about Amgen.
In the world of nearly 400 publicly-traded biotechs, analyst coverage is especially important. Many of the firms are micro caps and when an analyst initiates coverage it can help put a baby biotech on investor and reporter radar screens.
That's what worked in 1990, in an environment much like this one.
When combing through Barron's over the weekend I always make it a point to check out the "Short Interest" tables when they appear. I'm curious, in particular, about the ups and downs in Dendreon. Right now it's 39th on Barron's list of the Top-40 largest short positions.
GM's shares have plummeted to less than $12, the lowest level since 1955. That means the world's largest auto maker has a stock market value of only about $7 billion.
Stocks closed lower Monday, snapping last week's rally, amid a fresh wave of financial worries and inflation concerns. General Motors rose.
D-mab is a twice-a-year shot and Fosamax is a once-a-week pill. Doctors say compliance--patients taking their meds--is a challenge with the most common osteoporosis drugs in part because you have to take them with a tall glass of water and then stay upright for at least half an hour.